ASH 2020 | Worldwide access to efficacious agents in MDS needs improvement
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, shares his thoughts on the importance of making efficacious agents in myelodysplastic syndromes (MDS) available worldwide. Many resource-limited countries do not have access to agents with proven activity in MDS, such as hypomethylating agents. While further progress is being made in the west with studies of HMA-based combination therapy, a focus on improving worldwide availability of these agents is important. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting fees: Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol-Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead
